China NMPA Product Recall - Implantable deep brain stimulator

The National Medical Products Administration (NMPA) has announced a Class II voluntary recall initiated by Medtronic Inc., facilitated by Medtronic (Shanghai) Management Co., Ltd. Published on January 31, 2023, the recall pertains to specific models and batches of implantable deep brain stimulators. The core issue identified is a malfunction where certain products fail to restart properly after an initial operation or programming. This recall is a proactive measure by Medtronic to address a potential safety concern, ensuring patient well-being and product reliability. Although no specific inspection dates are detailed in the provided document, the company's decision to conduct a voluntary recall under the NMPA's oversight highlights adherence to regulatory expectations. The required action involves the recall of affected devices, with detailed information on specific models and batch numbers available in the attached "Medical Device Recall Event Report Form" for healthcare providers and patients to review. This action underscores Medtronic's commitment to product safety and regulatory compliance within the Chinese market.